FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology, and concerns atherosclerosis nutritive prevention and treatment ensured by introduction of BAAs "Pharmanex": LifePak dosed 1 pill in the morning and in the evening, MarineOmega® dosed 1 capsule in the morning; Tegreen97 dosed 1 capsule in the morning every second day within 8 weeks.
EFFECT: scheduled introduction of said specific BAAs provides mutual potentiation of their anti-oxidant, hypolipidemic and hypotensive properties.
3 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREVENTING THE DEVELOPMENT OF ATHEROSCLEROSIS | 2005 |
|
RU2290907C1 |
METHOD FOR INSULIN RESISTANCE CORRECTION IN METABOLIC SYNDROME | 2009 |
|
RU2402326C1 |
METHOD FOR CORRECTION OF DYSLIPIDEMIA IN WOMEN WITH METABOLIC SYNDROME DURING MENOPAUSAL TRANSITION | 2021 |
|
RU2771426C1 |
METHOD FOR LIPID METABOLISM CORRECTION IN INDIVIDUALS WITH RISK OF DEVELOPING ATHEROSCLEROSIS WITH USE OF MARE'S MILK, PHYTOCOMPLEX AND MINERAL WATER | 2012 |
|
RU2483738C1 |
METHOD OF LIPID METABOLIC DISORDER CORRECTION | 2007 |
|
RU2337696C1 |
METHOD FOR SELECTING THERAPY FOR CORRECTING LIPID METABOLISM DISORDERS IN CHRONIC PYELONEPHRITIS PATIENTS | 2005 |
|
RU2310864C2 |
WAY OF CORRECTION OF ENDOTHELIAL DYSFUNCTION | 2007 |
|
RU2359686C2 |
METHOD FOR CORRECTING METABOLIC DISORDERS IN PERIMENOPAUSAL WOMEN | 2021 |
|
RU2767879C1 |
METHOD FOR PATIENT-SPECIFIC PREDICTION OF OESTROGEN-DEPENDENT DISEASES IN HEALTHY FEMALES AND FEMALES WITH CARDIOVASCULAR RISK FACTORS AGED 35-45 YEARS | 2013 |
|
RU2536829C1 |
METHOD FOR DISLIPIDEMIA PREVENTION | 2016 |
|
RU2621152C1 |
Authors
Dates
2009-07-10—Published
2007-12-07—Filed